Significance: Given that (1) more than 387 million people worldwide are affected by Diabetes mellitus (DM); (2) the life-long painful injection/drug treatment is required to treat DM; and (3) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i) a way to preserve the functioning of adult β-cells in DM; and (ii) a drug that is free of side effects. This study suggests, for the first time, that MiRNA-17-5p, by increasing the expression of its target gene, it may increase anti-ageing gene Klotho expression. Thereby, it may: (1) improve human pancreatic beta cell functioning; (2) increase islet cell mass; and (3) improve glycemic control. Thus, pharmacological formulations encompassing “MiRNA-17-5p or its activators” may be used to (1) preserve the functioning of β-Cell in TIIDM; (2) and extend the life span of humans. Together, this study suggests, for the first time, a drug candidate–MiRNA-17-5p–that not only cures/treats DM, but also extends lifespan.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, MiRNA-based therapy for Preserving β-Cell functioning in DM and for extending life span of humans: MiRNA-17-5p increases the expression of antiaging and longevity gene Klotho, improves β-Cell function and prevents the development of T2DM via down regulation of its target gene, 23/April/2015, 7.23 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org
* Research cooperation
Undisclosed information: How MiRNA-17-5p increases the expression of Klotho